Benzinga · Apr 19, 2024
What Analysts Are Saying About DermTech Stock
DermTech (NASDAQ:DMTK) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 3 0 0 Last 30D 0 0 2 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 1 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $1.41, a high estimate of $2.00, and a low estimate of $0.63. A 56.62% drop is evident in the current average compared to the previous average price target of $3.25. Breaking Down Analyst Ratings: A Detailed Examination The perception of DermTech by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Thomas Flaten Lake Street Announces Hold $0.63 - Mason Carrico Stephens & Co. Maintains Equal-Weight $1.50 - Mark Massaro BTIG Lowers Buy $2.00 $4.00 Mason Carrico Stephens & Co. Lowers Equal-Weight $1.50 $2.50 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to ...Full story available on Benzinga.com
